

SCS SB 567 & 792 -- Clinical Trials

Sponsor: Dougherty

This substitute requires health insurers to cover routine patient care costs incurred as a result of phase II clinical trials for cancer treatment. Currently, coverage is only required for phase III and IV of these trials.